Scientists, led by the National University of Singapore and the University of Glasgow, have used the term ‘lateral transduction’ to describe a novel, dangerously-potent mechanism of bacteriophage-induced genetic transduction.
In this interview, we speak to to Keith Kaye, Principle Investigator of the RESTORE-1 trial assessing relebactam in combination with imipenem (IMI/REL), about the trial’s results and the implications these have for clinicians in ‘real world’ settings.
Nearly half of prescriptions for antibiotics were written without an infection-related diagnosis, according to a study of 509,534 prescriptions reported at IDWeek today.
The US FDA has approved Paratek Pharmaceuticals’ antibiotic Nuzyra™ (omadacycline) for the treatments of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
A Phase III study, TANGO II, has reported that meropenem–vaborbactam monotherapy for CRE infections was associated with improvement in clinical cure rates, lower nephrotoxicity and lower mortality versus best-available therapy.
GARDP and Novartis have announced a partnership hoping to accelerate the development and availability of generic antibiotics for children in LMICs.
Researchers from Genentech have carried out optimization of the arylomycins, uncovering a molecule with potent, broad-spectrum activity against Gram-negative bacteria.
In this interview, take a look behind the scenes of a recent Future Microbiology paper on the emergence of antifungal resistance and what can be done in response with author, Justin Beardsley.
In this interview, take a look behind the scenes of a recent Future Microbiology paper on antibiotic resistance targets for point-of-care diagnostics with author, John P. Hays.
Over 8000 combinations of four of five antibiotics have been demonstrated to be more effective than previously thought, according to new research.
